Document 0797
 DOCN  M9590797
 TI    Inhibition of clinical human immunodeficiency virus (HIV) type 1
       isolates in primary CD4+ T lymphocytes by retroviral vectors expressing
       anti-HIV genes.
 DT    9509
 AU    Vandendriessche T; Chuah MK; Chiang L; Chang HK; Ensoli B; Morgan RA;
       Clinical Gene Therapy Branch, National Cancer Institute,; Bethesda,
       Maryland 20892, USA.
 SO    J Virol. 1995 Jul;69(7):4045-52. Unique Identifier : AIDSLINE
       MED/95287453
 AB    Gene therapy may be of benefit in human immunodeficiency virus type 1
       (HIV-1)-infected individuals by virtue of its ability to inhibit virus
       replication and prevent viral gene expression. It is not known whether
       anti-HIV-1 gene therapy strategies based on antisense or transdominant
       HIV-1 mutant proteins can inhibit the replication and expression of
       clinical HIV-1 isolates in primary CD4+ T lymphocytes. We therefore
       transduced CD4+ T lymphocytes from uninfected individuals with
       retroviral vectors expressing either HIV-1-specific antisense-TAR or
       antisense-Tat/Rev RNA, transdominant HIV-1 Rev protein, and a
       combination of antisense-TAR and transdominant Rev. The engineered CD4+
       T lymphocytes were then infected with four different clinical HIV-1
       isolates. We found that replication of all HIV-1 isolates was inhibited
       by all the anti-HIV vectors tested. Greater inhibition of HIV-1 was
       observed with transdominant Rev than with antisense RNA. We hereby
       demonstrated effective protection by antisense RNA or transdominant
       mutant proteins against HIV-1 infection in primary CD4+ T lymphocytes
       using clinical HIV-1 isolates, and this represents an essential step
       toward clinical anti-HIV-1 gene therapy.
 DE    Acquired Immunodeficiency Syndrome/*THERAPY  CD4-Positive
       T-Lymphocytes/*VIROLOGY  *Gene Therapy  Genetic Vectors  Human
       HIV-1/*GENETICS  Retroviridae/GENETICS  RNA, Antisense/*THERAPEUTIC USE
       Support, Non-U.S. Gov't  Zidovudine/PHARMACOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).